🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. TRIPTORELIN, GONAPEPTYL 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée en seringues pré-remplies., LEUPRORELIN ACETATE, BAY 1841788, TRIPTORELIN, DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, DEGARELIX, LEUPRORELIN ACETATE

    The George Institute

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  2. TS-1 with cisplatin

    Hospital Authority, Hong Kong

    Recurrent Gastric Cancer

    phase 2 small molecule active

    1 trial

  3. TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets

    Ningbo Cancer Hospital

    Non-resectable locally advanced or metastatic HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  4. Tak-228 & Tak-117

    Takeda

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  5. Talazoparib Tosylate

    BioMarin Pharmaceutical Australia Pty Ltd

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  6. Tarlatamab

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Tarlatamab, TARLATAMAB, Tarlatamab, SILTUXIMAB

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Tarlatamab, Tarlatamab

    The George Institute

    Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)

    phase 2 small molecule active

    1 trial

  9. Tarlatamab, Tarlatamab

    Partner Therapeutics Limited

    Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2

    phase 2 small molecule active

    1 trial

  10. Tas-102(Suyuan) combined with bevacizumab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  11. Taxotere

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  12. Tecentriq 1 200 mg concentrate for solution for infusion

    Tour Hekla

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  13. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  14. Tecentriq 1 200 mg concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    Limited disease small-cell lung cancer

    phase 2 small molecule active

    1 trial

  15. Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Locally advanced cervical cancer

    phase 2 small molecule active

    1 trial

  16. Tecentriq 1 200 mg concentrate for solution for infusion, OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion., CAPECITABINE VIATRIS 500 mg, comprimé pelliculé

    CERO THERAPEUTICS HOLDINGS, INC.

    microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

    phase 2 small molecule active

    1 trial

  17. Tecentriq 1,200 mg concentrate for solution for infusion, EXL01, IMFINZI 50 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  18. Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  19. Tegafur Gimeracil Oteracil Potassium Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 small molecule active

    1 trial

  20. Telehealth Intervention

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 2 other active

    1 trial

  21. Telisotuzumab Vedotin

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  23. Temsirolimus

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  24. Teniposide administration

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources